participation of underrepresented populations: in cancer-related trials jean g. ford, m.d. associate...
TRANSCRIPT
![Page 1: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/1.jpg)
Participation of Underrepresented Populations:in Cancer-related Trials
Jean G. Ford, M.D.Associate Professor of EpidemiologyJohns Hopkins Bloomberg School of Public Health
![Page 2: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/2.jpg)
Objectives
■ Discuss results of evidence-based review
■ Highlight future directions for research
![Page 3: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/3.jpg)
Background
■ 1993 NIH Revitalization Act called for inclusion of women & minorities in all human subjects research
■ NCI budget nearly doubled from 1993 to 2002– Trial accrual increased– Not clear if all populations benefited
■ Some populations remain under-represented in NCI-funded clinical trials
![Page 4: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/4.jpg)
Key Questions
■ What are barriers & promoters for participation of underrepresented populations in cancer trials?
■ What effects do healthcare providers have on recruitment of under-represented populations?
■ What recruitment strategies are efficacious?■ What measures of recruitment success have
been used?■ What methods have been used to study
recruitment strategies?
![Page 5: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/5.jpg)
Conceptual Framework
Awareness
Opportunity
Acceptance/Refusal
AwarenessBarriers/
Promoters
Interventions
OpportunityBarriers/
Promoters
Moderators/Sociodemographic
Factors
Measuresof
Success
Acceptance/RefusalBarriers/
Promoters
StudyDesign
Ford JG Howerton MW, Powe NR, Bass EB, et al., Cancer. 2008; 112:228-42.
![Page 6: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/6.jpg)
Summary of Search
Electronic Databases
Retrieved5257
Title Review4928
Abstract Review1194
Article Review270
Hand Searching123
Duplicates341
Excluded3734
Excluded924
Excluded205
65 Articles Eligible
Barriers to Enrollment
![Page 7: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/7.jpg)
Barriers to & Promoters of Enrollment
Key Findings from 65 studies
![Page 8: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/8.jpg)
Study Characteristics
■ Dates published– < 1996: 10– 1996 – 2000: 14– 2001 – 2005: 41
■ Study Design:– Observational/Experimental: 9– Descriptive (registry reviews, surveys): 33– Qualitative (focus groups, semi-structured interviews): 24
■ Setting:– Hospital inpatient or outpatient: 43– Community: 33– Other: 7
![Page 9: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/9.jpg)
Study Characteristics (II)
■ Type of population:– African-American: 35– Older adults: 19– Latino/Hispanic: 12– Asian/Pacific Islander: 6– Native American / Alaskan Native: 4– Adolescent: 4– Rural: 2
■ US-based: 40
![Page 10: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/10.jpg)
Barriers to Awareness(N = 18 studies)
0
2
4
6
8
10
12
14
Education re.clinical trials
Culturallyappropriateinformation
Cancerknowledge
Physicianawareness
![Page 11: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/11.jpg)
Barriers to Opportunity(N = 34 studies)
0
5
10
15
20
25
Logistic
s
Eligib
ility
Lack o
f dis
semin
atio
n
Costs
Provi
der re
latio
nship
Provi
der c
harac
teris
tics
Comm
unicat
ion
Lack o
f pro
toco
ls
![Page 12: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/12.jpg)
Barriers to Acceptance(N = 36 studies)
02468
101214161820
Mis
trust
Fear
Culture
Family
Discom
fort
Provi
der-re
late
dCost
s
Transp
ortatio
nTim
e
Relig
ious b
elie
fs
Low h
ealth
lite
racy
![Page 13: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/13.jpg)
Barriers stastically associated with accrual to cancer trials
■ Awareness (n = 3)– Lack of education about clinical trials– Lack of knowledge about origins of cancer
■ Opportunity (n = 16)– Sociodemographic characteristics– Lack of health insurance– Exclusion criteria (age, comorbid conditions)– Provider referral– Managed care
■ Acceptance (n = 3)– Perceived harm– Loss of control– Nature of intervention– Time commitment– Loss of income– Transportation
Ford JG, et al., Cancer. 2008; 112:228-42.
![Page 14: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/14.jpg)
Other Key Findings onBarriers & Promoters
■ Available evidence mostly about accrual to therapeutic trials
■ Barriers to opportunity frequently reported for both prevention & treatment trials
■ Limited data on Latinos/Hispanics, Asian/Pacific Islanders, American Indians/Alaska Natives, older adults, & adolescents
■ Barriers differed across populations
![Page 15: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/15.jpg)
Relation of Barriers & Promoters to Conceptual Framework
■ Awareness:– 8 barriers
■ Opportunity to participate:– 88
■ Acceptance/refusal of participation:– 44
![Page 16: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/16.jpg)
Healthcare Provider Effects
Key Findings from 18 studies
Howerton MW, et al., Cancer. 2007; 109:465-76.
![Page 17: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/17.jpg)
Studies Reporting on Provider Barriers to- and Promoters of Clinical Trial Enrollment
0
2
4
6
8
10
12
14
16
18
Knowledge Attitudes Communication
![Page 18: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/18.jpg)
Studies Reporting on Provider Attitudes as Barriers to Clinical Trial Enrollment (n=15)
0
1
2
3
4
5
6
7
8
9
ProtocolAdherence
Patient Mistrust Patient Costs Data CollectionCosts/Burden
Eligibility Clinical Trials Patient (culturalcompetence)
![Page 19: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/19.jpg)
Studies Reporting on Provider Promoters of Clinical Trial Enrollment (n=7)
00.5
11.5
22.5
33.5
44.5
![Page 20: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/20.jpg)
Studies Reporting on Study Design Barriers (n=11)
0
1
2
3
4
5
6
7
8
9
Eligibility Protocol Length of study/visitstructure
![Page 21: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/21.jpg)
Healthcare System Barriers
■ Lack of minority investigators/personnel (n=1)
■ Lack of dissemination of study opportunities to providers (n=2)
■ Lack of cultural competence among providers and/or staff (n=1)
■ Lack of access to institutions conducting cancer trial (n=1)
![Page 22: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/22.jpg)
Efficacy of Recruitment Strategies
Key findings from 7 studies
Lai GY, et al. Clinical Trials. 2006; 3: 133-141.
![Page 23: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/23.jpg)
Types of Promoters (I)
■ Most frequently reported:– patient incentives (n = 6)– provider incentives (n = 3)– altruism (n = 6)– culturally relevant education about trials (n = 4)
■ 59 distinct promoters of enrollment into cancer clinical trials– 36 therapeutic trials only– 14 prevention trials only– 17 therapeutic and prevention trials
![Page 24: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/24.jpg)
Types of Promoters (II)
■ Promoters in relation to conceptual framework– 6 awareness– 29 opportunity– 25 acceptance
■ Levels at which promoters occur– 40 patient level– 12 provider level– 6 study design level– 2 healthcare system level
![Page 25: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/25.jpg)
Figure D: Studies reporting on promoters of the opportunity for underrepresented populations to participate in cancer-related trials (n =
21)
0
1
2
3
4
5
6
7
Cultural competence /communication
Inclusion criteria Logistics Healthcare context Other factors Demographic factors
# o
f st
ud
ies
All studies
Studies w ith Af rican American
Studies w ith Elderly
![Page 26: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/26.jpg)
Figure F: Studies reporting on promoters of acceptance of participation by underrepresented populations in cancer-re lated trials (n = 17)
0
1
2
3
4
5
6
7
8
9
10
Treatment /Treatment Process
Altruism Perceived benef its Familyconsiderations
Trust Other factors
# o
f st
ud
ies
All studies
Studies w ith Af rican American
Studies w ith Elderly
![Page 27: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/27.jpg)
Recruitment Strategies/Interventions
Author, Year
Target Population Recruitment Intervention
Moinpour, 2000
African Americans (Sites A-D); Latino/Hispanic (Site E)
■Minority recruiter
Linnan, 2002
Workers in a manufacturing company
■Active recruitment arm –Employees signed up to participate
■Passive at worksites–Company provided list of employee names & home phone #s
Brewster, 2002
Latina/Hispanic women
■Clinic registry vs. media campaign
![Page 28: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/28.jpg)
Recruitment Strategies/Interventions (II)
Author, Year Target Population
Recruitment Intervention
Ford, 2004 African Americans
4 increasingly intensive strategies ■Enhanced mailings ■Minority interviewers ■Letter & phone reminders■Church-based project sessions
Mandelblatt, 2005
Latinas ■5-10 minute educational counseling delivered by non-physician study staff + informational brochure■Informational brochure only
![Page 29: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/29.jpg)
Recruitment Strategies/Interventions (III)
Author, Year Target Population Recruitment Intervention
Paskett, 2002 Rural physicians in North Carolina & South Carolina
■Tumor-reporting system■Nurse facilitator■Quarterly newspapers■Health educator
Kimmick, 2005 Older adults
CALGB Physicians
■Standard information (control)■Educational intervention
–Educational symposium–Geriatric oncology educational materials–Monthly mailings & e-mails for 1 year–Case discussion seminar
![Page 30: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/30.jpg)
Results
Author Descriptor of Point Estimate Point Estimate
Moinpour, 2000
Change in Site A enrollment, 1995-1996
Change in Site B enrollment, 1995-1996
Change in Site C enrollment, 1995-1996
Change in Site D enrollment, 1995-1996
Change in Site E enrollment, 1995-1996
-0.3%
-0.5%
-1.8%
-0.6%
0.5%
![Page 31: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/31.jpg)
Results (II)
Author Descriptor of Point Estimate
Point Estimate(p value)
Linnan, 2002
Difference in enrollment 36.6% (p<0.0001)
Brewster, 2002
Odds ratio of women presenting in clinic
Odds ratio of women screened by telephone
3.00 (2.38, 3.78)
2.97 (2.52, 3.51)
Ford, 2004
Difference in enrollment (Arm C vs. Arm D)
1.0% (p<0.01)
![Page 32: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/32.jpg)
Results (III)
Author Descriptor of Point Estimate
Point Estimate(p value)
Mandelblatt, 2005
Intent to enroll in the STAR trial, intervention vs. control
■77% intent vs. 67% in intervention vs. control groups (P=0.03)
Kimmick, 2005
% enrollment of older adults, Intervention
% enrollment of older adults, Control
■Baseline: 40% (P=0.40)■Year 1: 36% (P=0.35)■Year 2: 31% (P=0.83)
■Baseline: 36%■Year 1: 32%■Year 2: 31%
![Page 33: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/33.jpg)
Results (IV)
Author Descriptor of Point Estimate Point Estimate
Paskett, 2002
Enrollment change of breast cancer patients, 1991-1996 (NC)
Enrollment change of colorectal cancer patients, 1991-1996 (NC)
Enrollment change of breast cancer patients, 1991-1996 (SC)
Enrollment change of colorectal cancer patients, 1991-1996 (SC)
-9%
1%
44%
-5%
![Page 34: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/34.jpg)
Recruitment Strategies/Interventions
UyBico SJ et al., JGIM 2007;22:852–863
![Page 35: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/35.jpg)
Limitations of Studies of Efficacy of Recruitment Interventions
■ Few studies available■ All published studies focused on
accrual to prevention trials■ Limited generalizability■ Intensity needed to modify behavior ■ Varying quality of study methods
![Page 36: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/36.jpg)
Summary
![Page 37: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/37.jpg)
Application of Evidence to Conceptual Framework
Awareness
Opportunity
Acceptance/Refusal
AwarenessBarriers/Promoters
Lack of education about CTs Lack of knowledge about
origins of cancer Culturally relevant education
about CTs Lack of physician awareness Health literacy
Interventions
Opportunity Barriers/Promoters
Protocol characteristics Eligibility Costs to patient Provider knowledge Provider attitudes/beliefs Lack of dissemination of
study opportunities topatient/provider
Data collection costs/burden Provider’s communication/
method of presentation
Moderators/Sociodemographic
FactorsRace/Ethnicity
AgeGender
GeographyLanguage
IncomeSES
EducationCulture
Measures of Success
Acceptance/RefusalBarriers/Promoters
Trust in sponsor/investigator Perceived harms/benefits Fear Family Costs Time Transportation Altruism Religious / spiritual beliefs Incentives Provider-related Stress
Study Design
![Page 38: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/38.jpg)
Overall Summary
■ More barriers to opportunity than to awareness or acceptance– More evidence on barriers than on promoters– Mistrust a common theme
■ Provider barriers at level of professionals, study design & healthcare system
■ Recruitment goals rarely reported a priori
![Page 39: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/39.jpg)
Limitations of Evidence■ Heterogeneity
– study design– data quality
■ Relationship between barriers & promoters unclear
■ Overlap between underrepresented populations■ More evidence from therapeutic trials than
prevention trials■ Excluded studies other than clinical trials ■ Recruitment experience not always reported
![Page 40: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/40.jpg)
Conclusions
■ In order to improve the knowledge base on accrual of underrepresented populations to clinical trials, hypothesis-driven studies are needed, with adequate power to detect differences.
■ The quality of the evidence can be improved by nesting recruitment studies within plans for conducting trials.
![Page 41: Participation of Underrepresented Populations: in Cancer-related Trials Jean G. Ford, M.D. Associate Professor of Epidemiology Johns Hopkins Bloomberg](https://reader038.vdocuments.us/reader038/viewer/2022110116/551afd7f5503462e578b5015/html5/thumbnails/41.jpg)
Principal Investigators:Jean G. Ford, MD
Mollie W. Howerton, PhD, MPH
Co-Investigators:Tiffany L. Gary, PhD, Gabriel Y. Lai, MHS.
Shari Bolen, MD, MPH, Jon Tilburt, MDM. Chris Gibbons, MD, MPH, Charles Baffi, PhD, MPH
Renee F. Wilson, MS, Carolyn J. FeuersteinPeter Tanpitukpongse, Neil R. Powe, MD, MPH, MBA
Eric B. Bass, MD, MPH
The EPC Team